Form 4: Armata Pharmaceuticals Corporate Controller and PFO Acquires Shares and Stock Options
SEC Form 4 Filing
Richard Rychlik, Corporate Controller and PFO of Armata Pharmaceuticals, reports acquisition of common stock and stock options.
Summary
- On March 14, 2024, Richard Rychlik, the Corporate Controller and PFO of Armata Pharmaceuticals, acquired 10,000 shares of common stock at $0.00.
- On the same date, Rychlik also acquired 40,000 stock options with an exercise price of $3.38, expiring on March 14, 2034.
- The stock options vest in four equal installments of 25% on March 14th of each year from 2025 to 2028.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating an officer's acquisition of shares and options, which could be seen as a positive signal, but it's not definitively bullish.
Positives
- The acquisition of shares and stock options by a key officer could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of shares by a company officer may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 03/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.